| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.876 | 0.005 | 0.876 | Angiogenesis inhibitor | 0.789 0.005 DBMET01384 0.87 0.005 DBMET02777 0.863 0.005 DBMET02778 | ||
| 0.852 | 0.004 | 0.856 | Platelet aggregation inhibitor | 0.795 0.004 DBMET01384 0.856 0.004 DBMET02777 0.848 0.004 DBMET02778 | DBMET02777 | |
| 0.836 | 0.002 | 0.9 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.801 0.002 DBMET01384 0.823 0.002 DBMET02777 0.9 0.002 DBMET02778 | DBMET02778 | |
| 0.819 | 0.003 | 0.819 | Platelet activating factor beta antagonist | 0.691 0.004 DBMET01384 0.809 0.003 DBMET02777 0.761 0.004 DBMET02778 | ||
| 0.802 | 0.003 | 0.802 | Platelet activating factor antagonist | 0.685 0.004 DBMET01384 0.798 0.003 DBMET02777 0.757 0.004 DBMET02778 | ||
| 0.699 | 0.005 | 0.699 | Vascular endothelial growth factor antagonist | 0.474 0.009 DBMET01384 0.677 0.005 DBMET02777 0.627 0.005 DBMET02778 | ||
| 0.697 | 0.003 | 0.697 | Platelet activating factor alpha antagonist | 0.565 0.003 DBMET01384 0.69 0.003 DBMET02777 0.63 0.003 DBMET02778 | ||
| 0.676 | 0.005 | 0.676 | Vascular endothelial growth factor 2 antagonist | 0.445 0.01 DBMET01384 0.65 0.005 DBMET02777 0.592 0.005 DBMET02778 | ||
| 0.654 | 0.004 | 0.663 | Vascular endothelial growth factor 3 antagonist | 0.533 0.005 DBMET01384 0.663 0.004 DBMET02777 0.63 0.004 DBMET02778 | DBMET02777 | |
| 0.617 | 0.004 | 0.617 | Fibroblast growth factor 1 antagonist | 0.449 0.004 DBMET01384 0.604 0.004 DBMET02777 0.565 0.004 DBMET02778 | ||
| 0.531 | 0.007 | 0.57 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.467 0.01 DBMET01384 0.533 0.007 DBMET02777 0.57 0.005 DBMET02778 | DBMET02778 | |
| 0.518 | 0.004 | 0.551 | MAP-kinase-activated kinase 5 inhibitor | 0.492 0.004 DBMET01384 0.526 0.004 DBMET02777 0.551 0.004 DBMET02778 | DBMET02778 | |
| 0.498 | 0.005 | 0.498 | Vascular endothelial growth factor 1 antagonist | 0.354 0.007 DBMET01384 0.461 0.005 DBMET02777 0.42 0.005 DBMET02778 | ||
| 0.515 | 0.022 | 0.522 | Calcium channel L-type activator | 0.257 0.197 DBMET01384 0.522 0.02 DBMET02777 0.375 0.099 DBMET02778 | DBMET02777 | |
| 0.455 | 0.002 | 0.464 | MAP kinase kinase 5 inhibitor | 0.427 0.002 DBMET01384 0.463 0.002 DBMET02777 0.464 0.002 DBMET02778 | DBMET02778 | |
| 0.502 | 0.053 | 0.503 | MAP kinase 1 inhibitor | 0.503 0.053 DBMET01384 0.421 0.094 DBMET02777 0.286 0.196 DBMET02778 | DBMET01384 | |
| 0.394 | 0.012 | 0.45 | Cyclin-dependent kinase inhibitor | 0.26 0.025 DBMET01384 0.443 0.009 DBMET02777 0.45 0.009 DBMET02778 | DBMET02778 | |
| 0.387 | 0.025 | 0.387 | Antimitotic | 0.223 0.072 DBMET01384 0.355 0.031 DBMET02777 0.291 0.046 DBMET02778 | ||
| 0.352 | 0.01 | 0.352 | Gastrin inhibitor | 0.316 0.023 DBMET01384 0.297 0.035 DBMET02777 0.33 0.017 DBMET02778 | ||
| 0.348 | 0.022 | 0.348 | Growth factor antagonist | 0.23 0.039 DBMET01384 0.312 0.026 DBMET02777 0.258 0.034 DBMET02778 | ||
| 0.319 | 0.005 | 0.319 | Platelet growth factor antagonist | 0.209 0.008 DBMET01384 0.291 0.005 DBMET02777 0.258 0.005 DBMET02778 | ||
| 0.322 | 0.028 | 0.322 | MAP kinase kinase 2 inhibitor | 0.304 0.034 DBMET02777 0.308 0.032 DBMET02778 | ||
| 0.285 | 0.022 | 0.285 | Protein-tyrosine kinase Lyn inhibitor | 0.22 0.039 DBMET01384 0.274 0.024 DBMET02777 0.248 0.03 DBMET02778 | ||
| 0.29 | 0.041 | 0.29 | Sigma receptor agonist | 0.168 0.074 DBMET01384 0.227 0.054 DBMET02777 0.16 0.079 DBMET02778 | ||
| 0.251 | 0.004 | 0.27 | Transforming growth factor antagonist | 0.226 0.004 DBMET01384 0.27 0.004 DBMET02777 0.263 0.004 DBMET02778 | DBMET02777 | |
| 0.208 | 0.013 | 0.208 | Insulin receptor antagonist | 0.113 0.048 DBMET01384 0.156 0.025 DBMET02777 0.148 0.028 DBMET02778 | ||
| 0.282 | 0.107 | 0.326 | Vasodilator, peripheral | 0.326 0.084 DBMET02777 0.239 0.136 DBMET02778 | DBMET02777 | |
| 0.186 | 0.015 | 0.192 | Breast cancer-resistant protein inhibitor | 0.125 0.036 DBMET01384 0.192 0.015 DBMET02777 0.144 0.026 DBMET02778 | DBMET02777 | |
| 0.159 | 0.003 | 0.159 | MAP kinase 7 inhibitor | 0.143 0.003 DBMET01384 0.145 0.003 DBMET02777 0.142 0.003 DBMET02778 | ||
| 0.178 | 0.028 | 0.205 | Aurora-C kinase inhibitor | 0.164 0.036 DBMET01384 0.179 0.027 DBMET02777 0.205 0.018 DBMET02778 | DBMET02778 | |
| 0.213 | 0.064 | 0.213 | Tyrosine kinase inhibitor | 0.135 0.098 DBMET01384 0.187 0.073 DBMET02777 0.166 0.082 DBMET02778 | ||
| 0.186 | 0.054 | 0.186 | Cytidine deaminase inhibitor | 0.162 0.067 DBMET01384 0.128 0.093 DBMET02777 | ||
| 0.18 | 0.05 | 0.18 | Lck kinase inhibitor | 0.137 0.074 DBMET01384 0.174 0.052 DBMET02777 0.164 0.057 DBMET02778 | ||
| 0.188 | 0.065 | 0.2 | Lipocortins synthesis antagonist | 0.183 0.068 DBMET01384 0.175 0.076 DBMET02777 0.2 0.056 DBMET02778 | DBMET02778 | |
| 0.181 | 0.064 | 0.181 | Src kinase inhibitor | 0.136 0.094 DBMET01384 0.166 0.073 DBMET02777 0.157 0.079 DBMET02778 | ||
| 0.235 | 0.12 | 0.235 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.223 0.133 DBMET02777 0.19 0.169 DBMET02778 | ||
| 0.182 | 0.071 | 0.235 | Amyloid beta precursor protein antagonist | 0.235 0.039 DBMET01384 0.155 0.095 DBMET02777 0.163 0.088 DBMET02778 | DBMET01384 | |
| 0.158 | 0.059 | 0.172 | Ribosomal protein S6 kinase inhibitor | 0.113 0.099 DBMET01384 0.163 0.056 DBMET02777 0.172 0.051 DBMET02778 | DBMET02778 | |
| 0.167 | 0.072 | 0.183 | Death-associated protein kinase 2 inhibitor | 0.174 0.062 DBMET02777 0.183 0.051 DBMET02778 | DBMET02778 | |
| 0.191 | 0.101 | 0.191 | Cyclic AMP phosphodiesterase inhibitor | 0.177 0.115 DBMET02777 0.181 0.11 DBMET02778 | ||
| 0.172 | 0.088 | 0.172 | P-glycoprotein inhibitor | 0.161 0.1 DBMET02777 | ||
| 0.111 | 0.027 | 0.111 | Fibroblast growth factor 3 antagonist | 0.098 0.034 DBMET02777 0.069 0.066 DBMET02778 | ||
| 0.294 | 0.221 | 0.441 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.322 0.185 DBMET02777 0.441 0.068 DBMET02778 | DBMET02778 | |
| 0.112 | 0.049 | 0.115 | MAP kinase 8 inhibitor | 0.084 0.082 DBMET01384 0.115 0.046 DBMET02777 0.103 0.057 DBMET02778 | DBMET02777 | |
| 0.129 | 0.068 | 0.129 | c-Src kinase inhibitor | 0.108 0.084 DBMET02777 0.105 0.086 DBMET02778 | ||
| 0.152 | 0.091 | 0.152 | Cyclin-dependent kinase 3 inhibitor | 0.137 0.132 DBMET02777 | ||
| 0.116 | 0.06 | 0.116 | Polo-like kinase-4 inhibitor | 0.091 0.087 DBMET02777 0.092 0.085 DBMET02778 | ||
| 0.193 | 0.139 | 0.193 | 5 Hydroxytryptamine 1E antagonist | |||
| 0.162 | 0.12 | 0.163 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.16 0.122 DBMET01384 0.144 0.135 DBMET02777 0.163 0.119 DBMET02778 | DBMET02778 | |
| 0.108 | 0.069 | 0.108 | Glycogen synthase kinase-3 beta inhibitor | 0.102 0.075 DBMET02777 0.104 0.073 DBMET02778 | ||
| 0.107 | 0.072 | 0.107 | Glycogen synthase kinase-3 inhibitor | 0.1 0.08 DBMET02777 0.098 0.081 DBMET02778 | ||
| 0.076 | 0.041 | 0.105 | Check point kinase 1 inhibitor | 0.105 0.026 DBMET02777 0.105 0.026 DBMET02778 | DBMET02778 | |
| 0.249 | 0.216 | 0.249 | Apoptosis agonist | |||
| 0.166 | 0.14 | 0.166 | ErbB-1 antagonist | |||
| 0.078 | 0.052 | 0.109 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.104 0.033 DBMET02777 0.109 0.031 DBMET02778 | DBMET02778 | |
| 0.102 | 0.077 | 0.11 | MAP kinase 13 inhibitor | 0.11 0.066 DBMET02777 0.109 0.068 DBMET02778 | DBMET02777 | |
| 0.154 | 0.132 | 0.157 | Dyrk kinase inhibitor | 0.15 0.136 DBMET01384 0.157 0.129 DBMET02778 | DBMET02778 | |
| 0.081 | 0.061 | 0.106 | MAP-kinase-activated kinase inhibitor | 0.106 0.034 DBMET02777 0.106 0.034 DBMET02778 | DBMET02778 | |
| 0.067 | 0.048 | 0.082 | Protein kinase C alpha inhibitor | 0.076 0.038 DBMET02777 0.082 0.033 DBMET02778 | DBMET02778 | |
| 0.046 | 0.027 | 0.06 | Cholecystokinin antagonist | 0.037 0.031 DBMET02777 0.06 0.019 DBMET02778 | DBMET02778 | |
| 0.151 | 0.135 | 0.151 | Aryl hydrocarbon receptor agonist | |||
| 0.141 | 0.13 | 0.158 | Catenin beta inhibitor | 0.158 0.088 DBMET01384 0.151 0.104 DBMET02777 0.157 0.091 DBMET02778 | DBMET01384 | |
| 0.147 | 0.137 | 0.147 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | |||
| 0.027 | 0.035 | 0.034 | Cholecystokinin A antagonist | 0.034 0.029 DBMET02778 | DBMET02778 | |
| 0.04 | 0.048 | 0.048 | Transforming growth factor beta 1 antagonist | 0.048 0.036 DBMET02777 0.044 0.04 DBMET02778 | DBMET02777 | |
| 0.022 | 0.031 | 0.031 | Cholecystokinin B antagonist | 0.031 0.02 DBMET02778 | DBMET02778 | |
| 0.074 | 0.093 | 0.079 | 3C-Like protease (SARS coronavirus) inhibitor | 0.079 0.072 DBMET02778 | DBMET02778 | |
| 0.037 | 0.065 | 0.051 | CDK4/cyclin D1 inhibitor | 0.051 0.047 DBMET02778 | DBMET02778 | |
| 0.084 | 0.118 | 0.099 | MAP kinase kinase inhibitor | 0.099 0.096 DBMET02778 | DBMET02778 | |
| 0.023 | 0.078 | 0.098 | NMDA 2A receptor antagonist | 0.045 0.043 DBMET02777 0.098 0.014 DBMET02778 | DBMET02778 | |
| 0.007 | 0.109 | 0.023 | Kainate receptor 3 antagonist | 0.023 0.007 DBMET01384 | DBMET01384 | |
| 0.012 | 0.122 | 0.026 | NMDA 2D receptor antagonist | 0.026 0.021 DBMET02778 | DBMET02778 | |
| 0.007 | 0.145 | 0.049 | Kainate receptor 4 antagonist | 0.049 0.007 DBMET01384 | DBMET01384 | |
| 0.006 | 0.155 | 0.044 | Kainate receptor 5 antagonist | 0.044 0.006 DBMET01384 | DBMET01384 | |
| 0.008 | 0.175 | 0.039 | Kainate receptor antagonist | 0.039 0.03 DBMET02778 | DBMET02778 | |
| 0.017 | 0.188 | 0.048 | Plasminogen activator inhibitor antagonist | 0.048 0.035 DBMET01384 | DBMET01384 | |
| 0.01 | 0.231 | 0.079 | NMDA 2 receptor antagonist | 0.079 0.044 DBMET02778 | DBMET02778 | |
| 0.021 | 0.267 | 0.074 | NMDA receptor antagonist | 0.074 0.073 DBMET02778 | DBMET02778 | |
| 0.031 | 0.306 | 0.095 | Ferrochelatase inhibitor | 0.095 0.076 DBMET02778 | DBMET02778 | |
| 0.023 | 0.33 | 0.143 | M17 leucyl aminopeptidase inhibitor | 0.143 0.06 DBMET01384 | DBMET01384 | |
| 0.005 | 0.434 | 0.034 | AMPA 2 receptor antagonist | 0.034 0.018 DBMET01384 | DBMET01384 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |